Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus dual antiplatelet therapy after percutaneous PFO or ASD closure
NL-OMON58924Phase 2Not yet recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- May 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in patent foramen ovale (PFO) and atrial septal defect (ASD) comparing Dual antiplatelet therapy with Rivaroxaban (2 arms). Primary endpoints: Coagulation activation, Platelet activation and 6 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
rivaroxabanaspirin + P2Y12 antagonist
03
Conditions
patent foramen ovale (PFO)atrial septal defect (ASD)
Beyond the preview
Go deeper on NL-OMON58924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58924.